New injection aims to heal scarred livers in major trial
NCT ID NCT07145151
Summary
This study is testing an investigational injection called UBT251 to see if it can improve liver health in adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH), a serious form of fatty liver disease. About 156 participants will receive either UBT251 at one of three doses or a placebo for 48 weeks to see if the drug helps resolve liver inflammation and scarring. The main goal is to see if UBT251 leads to measurable improvement in liver tissue samples taken before and after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua ChangGung Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.